Optibiotix Health Share Discussion Threads

[pj 1] 30/11/2024 12:11

It seems bizarre to me that SOH didnt reference SWEETBIOTIX (or modulators) given all his previous hype, in his comments. It's almost as if point 4 has just been dropped in as a cover?

[jmf69] 30/11/2024 12:05

Plenty of raises to get us to where we are now. If we don't get positive news on sweetbiotix by the end of December, then I'll be out with a hefty loss

[pj 1] 30/11/2024 11:58

Really for my own reference for SWEETBIOTIX


30 May 2018 PLACING. Company has raised £1,500,000

As highlighted in its annual report the Company's cash position remains strong with sufficient funds to deliver on existing plans. However, growing commercial interest in the Company's award winning technology and products have generated new opportunities which if capitalised on have the potential for significant value enhancement. These include:-





· The development of the Company's cholesterol and blood pressure reducing strain LPLDL® as a pharmaceutical product. Under existing plans OptiBiotix's products have been developed for the ingredient and supplements market. Following on from the deal with Akums (as announced on 16 May 2018) the Company has received partner interest to license LPLDL® as a pharmaceutical product in the USA and a number of other international markets. Whilst partners will fund regulatory submissions and clinical studies, there is a requirement for OptiBiotix to invest in developing process controls and quality procedures to comply with pharmaceutical production of LPLDL®.


· OptiBiotix reported interest from a number of corporate partners in its SWEETBIOTIX product development (as announced on 27 March 2018). These include manufacturing partners and application developers who want to use SWEETBIOTIX in a wide range of dairy, bread, cereal, and beverage applications. To enable OptiBiotix to meet multiple partner needs and to fully exploit all opportunities additional scientific support is needed to complement the current team.


· The Company has received widespread industry recognition and awards for its SlimBiome® product which has now been incorporated into a wide range of applications. This is part of a process of extending SlimBiome® into a broader range of Health and Wellbeing food and beverage products and attract major retail interest. In order to list SlimBiome® as an own label or branded product in one or more major retailers requires funds to support upfront manufacturing and stocking
costs.
------------------------------------------------------------------------------------

27 March 2019 SWEETBIOTIX: Scientific and commercial update

In addition to ongoing discussion with existing partners, OptiBiotix has reached non-binding Heads of Terms with a US company to license OptiBiotix's high intensity derived sweeteners. This company has funded the pilot scale up and supply of two batches of high intensity derived sweeteners. Once a binding commercial agreement has been reached, this will be announced to the market. Late stage discussions are ongoing with another global partner to jointly develop a finished product which allows claim for sugar and calorie reduction whilst limiting any cost increase in the final product to 10%.

These discussions with multiple, often competing partners, are taking place against a background of continued development of the science which is identifying new functionalities and creating new opportunities. This creates a complexity in negotiating separate manufacturing and application rights for both high intensity sweeteners, bulk sugars and combinations of both. These discussions are with corporate partners within a corporate process and timescale, and are often subject to strict confidentiality clauses.
-----------------------------------------------------------------------------

17 April 2020 PLACING. Company has raised £1.0 million

- Launch its award-winning products in China, the USA, and India with partners who have an international reputation and significant retail network. Large retail partners deliver large volume sales but require a reliable and highly flexible supply chain and often have long payment terms. This requires OptiBiotix to build higher than anticipated stock levels to support upfront manufacturing and stocking costs;


- Support the launch of product lines extensions with existing partners (Alfasigma, Holland and Barrett, and Agropur) and new product launches planned for Australia with Optipharm;


- Scale up additional SWEETBIOTX products®. OptiBiotix has developed a number of natural sweet fibres (SweetBiotix®) with a clean flavour profile which increase the diversity of microbial species associated with good gut health. One of these products has undergone manufacturing scale up with a US corporate partner. Discussions are ongoing with a number of corporate partners who want to use different SWEETBIOTX products in a range of dairy, cereal, and beverage applications. To enable OptiBiotix to meet multiple partner needs and to fully exploit the wide range of applications opportunities OptiBiotix wishes to scale up additional SWEETBIOTIX products,


- Expand the presence and awareness of its products in the USA. As previously announced, the Company continues to explore the potential for a dual listing in those markets where there is potential for greater liquidity and valuation. To support this opportunity, create market interest, and improve international research coverage it intends to increase the presence and awareness of its brands and products in the USA.
------------------------------------------------------------------------------

15 September 2020. SWEETBIOTIX sweet fibres agreement

The agreement grants the US Company an exclusive worldwide license in return for it bearing the costs relating to product manufacturing, marketing, and all future costs relating to the commercialisation of a number of SWEETBIOTIX products.





OptiBiotix will receive a modest six-figure payment from the Company on signing the agreement and at 12 monthly intervals until product launch. Additional similar payments will be due on product launch plus royalties on all future product sales. Enhanced royalty payments will be made to OptiBiotix on sale of SWEETBIOTIX products by the Company to 11 application/innovation partners with whom OptiBiotix has been in long term discussions regarding exploring the use of SweetBiotix® products in dairy, cereal and beverage applications.

The US Company requires its identity and certain commercial terms of the agreement to remain confidential to protect its commercial launch plans.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this agreement for SWEETBIOTIX, a family of products based on the concept of creating a sweet fibre with a low glycaemic index which enhances the microbiome. The agreement allows the US Company to invest in the large scale manufacture and commercialisation of a number of SWEETBIOTIX products in return for upfront, annual and product launch milestone payments, plus royalties on all future product sales.
-------------------------------------------------------------------------

25 March 2024 PLACING. announces it has raised in aggregate £1,350,500

The net proceeds of the Fundraise will be utilised to invest in driving sales growth by:-



1. active account management of existing partners by co-investing in publicity, marketing, and promotions to increase sales;

2. increased presence of the Company's stands at major exhibitions to attract new partners, particularly in the USA and India to mitigate dependency on a small number of partners;

3. investing in marketing the Company's products to grow sales on e-commerce platforms in India, China, USA, Europe, and the Gulf States; and

4. launch its second generation SWEETBIOTIX and MicroBiome Modulator products.

Stephen O'Hara, CEO of OptiBiotix, commented: "The Company has made strong progress over the last 12 months with our first-generation products returning to sales growth, a number of well-known corporate partners reaching agreements (e.g. Tata, Brenntag, Morepen) and the launch of new products with major brands (MuscleTech, Dr Morepen) in new channels. We are also seeing growth of online sales, particularly in China, and the potential to replicate this success in other territories, such as India and the USA.

"More recently we have seen strong interest in SlimBiome from partners in the USA looking for a natural, clinically proven alternative to the anti-obesity drugs currently available. Given the scale of the opportunities, the Board has decided to raise additional capital to capitalise on these growth opportunities and build shareholder value."

[putinaire] 29/11/2024 16:40

Maker is more transparent than pinnochio's glass nose

DId somebody slate this one? Seems to be a panic lift to sell since

[putinaire] 28/11/2024 18:16

This could get embarrassing if i go through all calls really

Suffice to say Fkn LOL

'experts'

[putinaire] 28/11/2024 17:55

Here is an idea. You could identify the earnings report with the most BS. Everything under it thereafter is a trade. If ever above, maybe more. That wont ever happen of course

[putinaire] 28/11/2024 17:51

It's so potent, it has to remain classified

[putinaire] 28/11/2024 17:49

'If only you could see what i see now.............'

[putinaire] 28/11/2024 17:47

You should all sign a petition, requesting 1 image per decade, thats of use, rather than fkn reams of vile bile and sunday church footnotes

[putinaire] 28/11/2024 17:44

Do you know, just saw something



Maybe that one image could have saved reading the Orangutans articles for half a decade?

Some SR here was always shorting around those points back then? Mad haha

[putinaire] 28/11/2024 14:47

Of course, that would be manipulated share price for a pre-planned RNS within such a window.

That would be illegal you know

[putinaire] 28/11/2024 14:46

The only positive i can think of, is that an RNS is planned for within the next 1-5 market days. And they want share price above double barrel earnings so it's not sold off at them

Il check that later

[putinaire] 28/11/2024 14:42

Il ask the yanks to strip that chart. They can basically do it with 2 prices showing. Very precise dudes

[putinaire] 28/11/2024 14:41

The 'no reason ' rise in July, like past July's, kills the hope of 3rd earnings target re done already for selling. Be pushing it to try sell such again in same H

[putinaire] 28/11/2024 14:39

Conclusion

The Maker/OPTI need to switch bad sentiment created at past times like earnings, into selling opportunities for clients re flip that old sentiment into positive (do it where bad sentiment was put in mind)

Very common pre raises or some other dirt

[putinaire] 28/11/2024 14:33

Earnings always adjust down, so the PI's averages are lower down

So it cant go 3rd earnings here or you are in PI sell zone, when you want the dump liquidity for clients

Only thing you can do as maker, is work out if the selling PI's are outweighed by buying PI's at 3rd earnings. They have the orders to work that out.

I would doubt it personally

[putinaire] 28/11/2024 14:30

Really would take some balls to go for maker to go for it twice in a year. + no fear of the regulator but i guess that is a given anyway.

[putinaire] 28/11/2024 14:27

No attack on earnings 3 yet. Would be so so unusual having being done recently already before the last sell off